WallStSmart

Endava Ltd (DAVA)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Endava Ltd generates 187% more annual revenue ($743.90M vs $258.90M). DAVA leads profitability with a -0.4% profit margin vs -15.5%. DAVA earns a higher WallStSmart Score of 43/100 (D).

DAVA

Hold

43

out of 100

Grade: D

Growth: 3.3Profit: 2.5Value: 6.7Quality: 8.0
Piotroski: 5/9Altman Z: 3.01

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for DAVA.

ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DAVA3 strengths · Avg: 10.0/10
PEG RatioValuation
0.4310/10

Growing faster than its price suggests

Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
3.0110/10

Safe zone — low bankruptcy risk

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

DAVA4 concerns · Avg: 2.3/10
Market CapQuality
$229.34M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-0.5%2/10

ROE of -0.5% — below average capital efficiency

Revenue GrowthGrowth
-5.9%2/10

Revenue declined 5.9%

EPS GrowthGrowth
-21.4%2/10

Earnings declined 21.4%

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : DAVA

The strongest argument for DAVA centers on PEG Ratio, Price/Book, Altman Z-Score. PEG of 0.43 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : DAVA

The primary concerns for DAVA are Market Cap, Return on Equity, Revenue Growth.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

DAVA profiles as a turnaround stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - INFRASTRUCTURE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DAVA scores higher overall (43/100 vs 41/100). ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Endava Ltd

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Endava plc provides technology services for clients in the consumer products, healthcare, logistics and retail sectors in Europe, Latin America and North America. The company is headquartered in London, United Kingdom.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?